查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1365714

外泌体诊断与治疗市场：按用途、按产品、最终用户：2021-2030 年全球机会分析与产业预测

Exosome Diagnostic and Therapeutic Market By Application, By Product, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2030
出版日期: | 出版商: Allied Market Research | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

2020年外泌体诊断与治疗市值为2.2434亿美元，预计2021年至2030年年复合成长率为29.4%，到2030年达到29亿美元。

外泌体的用途与免疫反应、病毒发病机制、怀孕、心血管疾病、中枢神经系统相关疾病和癌症进展有关。外泌体有两种用途：诊断和治疗。外泌体诊断和治疗技术中使用的产品分为三类：设备、试剂和软体。

外泌体诊断与治疗市场-IMG1

此外，中国和印度等新兴国家预计将为该市场提供重大成长机会。外泌体诊断和治疗市场按用途、产品、最终用户和地区进行细分。依用途分为诊断用途和治疗用途。按产品分为设备、试剂、软体。依最终使用者分为癌症研究机构、医院、诊断中心和其他（医科大学、非营利组织）。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。北美在2020年占据市场主导地位，由于研发投资增加、外泌体分离程序技术进步以及癌症罹患率上升要素，预计在预测期内将保持其主导地位。此外，亚太地区正在经历开发中国家主要参与企业兴趣的增加、临床研究和试验外包的增加、人们健康意识和关注度的提高、癌症和其他疾病发病率的急剧上升。预计将成为最具增长潜力的地区。

本报告涵盖了外泌体诊断和治疗市场的主要企业：Aethlon Medical, Inc.（美国）、Exosome Diagnostics Inc.（美国）、NanoSomix Inc.（美国）、Thermo Fisher Scientific Inc.（英国）、System Biosciences Inc.（美国）、NX Pharmagen（美国）、Sistemic Inc.（英国）、Capricor Therapeutics（美国）、Exiqon A/S（丹麦）。

目录

第1章简介

第2章执行摘要

第3章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响要素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 慢性病增加
      • 癌症患病增加
      • 老年人口增加
    • 抑制因素
      • 外泌体诊断和治疗技术缺乏产品认证
    • 机会
      • 更多采用关键策略
  • COVID-19 市场影响分析

第4章外泌体诊断与治疗市场：依用途

  • 概述
  • 诊断
  • 治疗

第5章外泌体诊断与治疗市场：按产品

  • 概述
  • 装置
  • 试剂
  • 软体

第6章体外诊断与治疗市场：依最终使用者分类

  • 概述
  • 癌症研究所
  • 医院
  • 诊断中心
  • 其他的

第7章外泌体诊断与治疗市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第8章竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争仪表板
  • 竞争热图
  • 2020年主要企业定位

第9章公司简介

  • Aethlon Medical, Inc.
  • Exosome Diagnostic, Inc.
  • NanoSomix, Inc
  • Thermo Fisher Scientific, Inc.
  • Malvern Instruments Ltd
  • System Biosciences, Inc
  • NX Pharmagen, Inc.
  • Sistemic Ltd
  • Capricor Therapeutics, Inc.
  • Exiqon A/S
Product Code: A01396

According to a new report published by Allied Market Research, titled, "Exosome Diagnostic and Therapeutic Market," The exosome diagnostic and therapeutic market was valued at $224.34 million in 2020, and is estimated to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes are used in two applications, which includes diagnostic and therapeutic. There are three types of products used in exosomes diagnostic and therapeutic technique, which include instrument, reagent, and software.

Exosome Diagnostic and Therapeutic Market - IMG1

Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.

The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Product Benchmarking / Product specification and applications
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Diagnostic
  • Therapeutic

By Product

  • Instrument
  • Reagent
  • Software

By End User

  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Thermo Fisher Scientific, Inc.
    • Malvern Instruments Ltd
    • NX Pharmagen, Inc.
    • Sistemic Ltd
    • Exosome Diagnostic, Inc.
    • Capricor Therapeutics, Inc.
    • NanoSomix, Inc
    • System Biosciences, Inc
    • Exiqon A/S
    • Aethlon Medical, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of chronic diseases
      • 3.4.1.2. Increase in prevalence of cancer
      • 3.4.1.3. Rise in number of geriatric populations
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of product approvals for exosome diagnostic and therapeutic technique
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in adoption of key strategies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Diagnostic
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Therapeutic
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Instrument
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Reagent
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Software
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cancer Institute
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Hospital
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Diagnostic Center
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Application
    • 7.2.3. Market size and forecast, by Product
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Product
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Product
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Product
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Application
    • 7.3.3. Market size and forecast, by Product
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Product
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Product
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. U.K.
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Product
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Product
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Product
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Product
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Application
    • 7.4.3. Market size and forecast, by Product
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Product
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Product
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. Rest of Asia-Pacific
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Product
      • 7.4.5.3.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Application
    • 7.5.3. Market size and forecast, by Product
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Product
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Product
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Product
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Product
      • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2020

CHAPTER 9: COMPANY PROFILES

  • 9.1. Aethlon Medical, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Key strategic moves and developments
  • 9.2. Exosome Diagnostic, Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Key strategic moves and developments
  • 9.3. NanoSomix, Inc
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Thermo Fisher Scientific, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Malvern Instruments Ltd
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. System Biosciences, Inc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. NX Pharmagen, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. Sistemic Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Capricor Therapeutics, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Exiqon A/S
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 02. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 05. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 09. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 15. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 16. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 17. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 18. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 19. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 20. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 21. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 22. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 23. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 24. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 26. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 27. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 28. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 29. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 30. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 31. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 32. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 33. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 34. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 35. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 36. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 38. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 39. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 40. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 41. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 42. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 44. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 45. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 47. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 48. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 50. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 51. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 52. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 53. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 54. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 55. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 56. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 57. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 58. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 59. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 60. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 61. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 63. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 64. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 65. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 66. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 67. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 68. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 69. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 70. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 71. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 72. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 73. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 74. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 75. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 76. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 77. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 78. AETHLON MEDICAL, INC.: KEY EXECUTIVES
  • TABLE 79. AETHLON MEDICAL, INC.: COMPANY SNAPSHOT
  • TABLE 80. AETHLON MEDICAL, INC.: PRODUCT SEGMENTS
  • TABLE 81. AETHLON MEDICAL, INC.: PRODUCT PORTFOLIO
  • TABLE 82. AETHLON MEDICAL, INC.: KEY STRATERGIES
  • TABLE 83. EXOSOME DIAGNOSTIC, INC.: KEY EXECUTIVES
  • TABLE 84. EXOSOME DIAGNOSTIC, INC.: COMPANY SNAPSHOT
  • TABLE 85. EXOSOME DIAGNOSTIC, INC.: PRODUCT SEGMENTS
  • TABLE 86. EXOSOME DIAGNOSTIC, INC.: PRODUCT PORTFOLIO
  • TABLE 87. EXOSOME DIAGNOSTIC, INC.: KEY STRATERGIES
  • TABLE 88. NANOSOMIX, INC: KEY EXECUTIVES
  • TABLE 89. NANOSOMIX, INC: COMPANY SNAPSHOT
  • TABLE 90. NANOSOMIX, INC: PRODUCT SEGMENTS
  • TABLE 91. NANOSOMIX, INC: PRODUCT PORTFOLIO
  • TABLE 92. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 93. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 94. THERMO FISHER SCIENTIFIC, INC.: PRODUCT SEGMENTS
  • TABLE 95. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 96. MALVERN INSTRUMENTS LTD: KEY EXECUTIVES
  • TABLE 97. MALVERN INSTRUMENTS LTD: COMPANY SNAPSHOT
  • TABLE 98. MALVERN INSTRUMENTS LTD: PRODUCT SEGMENTS
  • TABLE 99. MALVERN INSTRUMENTS LTD: PRODUCT PORTFOLIO
  • TABLE 100. SYSTEM BIOSCIENCES, INC: KEY EXECUTIVES
  • TABLE 101. SYSTEM BIOSCIENCES, INC: COMPANY SNAPSHOT
  • TABLE 102. SYSTEM BIOSCIENCES, INC: PRODUCT SEGMENTS
  • TABLE 103. SYSTEM BIOSCIENCES, INC: SERVICE SEGMENTS
  • TABLE 104. SYSTEM BIOSCIENCES, INC: PRODUCT PORTFOLIO
  • TABLE 105. NX PHARMAGEN, INC.: KEY EXECUTIVES
  • TABLE 106. NX PHARMAGEN, INC.: COMPANY SNAPSHOT
  • TABLE 107. NX PHARMAGEN, INC.: PRODUCT SEGMENTS
  • TABLE 108. NX PHARMAGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 109. SISTEMIC LTD: KEY EXECUTIVES
  • TABLE 110. SISTEMIC LTD: COMPANY SNAPSHOT
  • TABLE 111. SISTEMIC LTD: PRODUCT SEGMENTS
  • TABLE 112. SISTEMIC LTD: PRODUCT PORTFOLIO
  • TABLE 113. CAPRICOR THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 114. CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 115. CAPRICOR THERAPEUTICS, INC.: SERVICE SEGMENTS
  • TABLE 116. CAPRICOR THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 117. EXIQON A/S: KEY EXECUTIVES
  • TABLE 118. EXIQON A/S: COMPANY SNAPSHOT
  • TABLE 119. EXIQON A/S: PRODUCT SEGMENTS
  • TABLE 120. EXIQON A/S: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030
  • FIGURE 02. SEGMENTATION OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030
  • FIGURE 03. TOP INVESTMENT POCKETS IN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET (2021-2030)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 17. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2020 AND 2030(%)
  • FIGURE 22. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION, 2020(%)
  • FIGURE 23. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 24. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 26. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 27. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 28. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 29. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 30. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 31. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 32. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 33. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 35. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 36. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 37. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 38. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2020
  • FIGURE 46. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 47. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 48. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 49. CAPRICOR THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)